Literature DB >> 8835287

Differential interactions of cytochalasins with P-glycoprotein.

J T Zilfou1, C D Smith.   

Abstract

Cytochalasins are a family of structurally related natural product cytotoxins that selectively depolymerize microfilaments. In this study, the interaction between several cytochalasins and the drug transporter P-glycoprotein was investigated. Dihydrocytochalasin B and cytochalasin E consistently sensitized P-glycoprotein-overexpressing human breast carcinoma cells (MCF-7/ADR) to daunomycin, vinblastine, and actinomycin D without affecting the cytotoxicity of cisplatin. These compounds did not affect the sensitivities of the parental MCF-7 cells to anticancer drugs, indicating that their effects are due to P-glycoprotein inhibition. Effects of dihydrocytochalasin B and cytochalasin E were observed at concentrations as low as 2.5 and 5 microM, respectively. In contrast, cytochalasins A, B, C, D, H, and J did not sensitize MCF-7/ADR cells to any of the drugs. The accumulation of [3H]-vinblastine by MCF-7/ADR cells and by drug-resistant human ovarian carcinoma cells (SKVLB1) was increased to the greatest extent by verapamil, followed by dihydrocytochalasin B > cytochalasin E > cytochalasin B, whereas cytochalasins A, C, D, H, and J did not alter intracellular accumulation of the drug. Similarly to verapamil, dihydrocytochalasin B significantly stimulated the ATPase activity of P-glycoprotein, while other cytochalasins were ineffective. These results demonstrate that very closely related compounds can differentially interact with P-glycoprotein. For example, the only difference between cytochalasin B and dihydrocytochalasin B is the saturation of a carbon-carbon double bond in dihydrocytochalasin B. These structural differences may provide important insight into chemical determinants for drug interaction with P-glycoprotein.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8835287

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  5 in total

1.  2-Amino-4-methyl-5-phenylethyl substituted-7-N-benzyl-pyrrolo[2,3-d]pyrimidines as novel antitumor antimitotic agents that also reverse tumor resistance.

Authors:  Aleem Gangjee; Ojas A Namjoshi; Staci N Keller; Charles D Smith
Journal:  Bioorg Med Chem       Date:  2011-05-23       Impact factor: 3.641

2.  Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells.

Authors:  S Ranganathan; C A Benetatos; P J Colarusso; D W Dexter; G R Hudes
Journal:  Br J Cancer       Date:  1998-02       Impact factor: 7.640

3.  Discovery of novel antitumor antimitotic agents that also reverse tumor resistance.

Authors:  Aleem Gangjee; Jianming Yu; Jean E Copper; Charles D Smith
Journal:  J Med Chem       Date:  2007-06-14       Impact factor: 7.446

4.  A unique cytosolic activity related but distinct from NQO1 catalyses metabolic activation of mitomycin C.

Authors:  P Joseph; A K Jaiswal
Journal:  Br J Cancer       Date:  2000-04       Impact factor: 7.640

5.  A Machine Learning-Based Prediction Platform for P-Glycoprotein Modulators and Its Validation by Molecular Docking.

Authors:  Onat Kadioglu; Thomas Efferth
Journal:  Cells       Date:  2019-10-21       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.